A Phase 2 interventional study of Curcumin and Placebo in Chronic Kidney Diseases, Blood Pressure and Hyperemia, sponsored by University of Iowa. Withdrawn. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-02-21.
Sponsored by University of Iowa · Phase 2, Interventional, and Treatment
Chronic kidney disease (CKD) is associated with a pro-oxidative and pro-inflammatory state, and this is thought to contribute to a decrease in vascular function leading to greater cardiovascular disease (CVD) risk. Curcumin supplementation has been shown to reduce oxidative stress and improve endothelial function at rest in healthy older humans, although the magnitude of this effect remains unknown during exercise in CKD. The primary aim of this proposal is to determine whether exercising blood flow and vasoconstrictor responsiveness are improved as a result of acute oral supplementation with curcumin in patients with CKD. We hypothesize that: 1) acute curcumin supplementation will increase steady state exercise blood flow, and 2) reduce vasoconstriction induced by an acute sympathetic stimulus (cold pressor test) CKD.
Active muscles require an optimal amount of local blood flow to meet the functional and metabolic demand of the exercising muscle. It is well known that maximal aerobic work capacity and exercise tolerance are reduced in CKD, contributing to functional impairment and loss of independence. A multitude of factors may be responsible for this outcome including reduced blood flow to active muscle beds brought on by greater levels of oxidative stress in CKD. Aging and some individuals with disease (coronary artery disease, hypertension, diabetes) exhibit elevated resting sympathetic nerve activity (SNA), leading to greater vasoconstriction and pressor responses during exercise. However, the magnitude of this effect remains unknown in CKD. Importantly, there are a lack of interventions aimed at improving blood flow and reduce sympathetic mediated vasoconstriction in patients with CKD.
Recent evidence in aging humans suggest that curcumin supplementation improves vascular function by reducing oxidative stress. However, it remains unknown whether acute curcumin supplementation can be regarded as an effective therapeutic strategy aimed at modulating exercise vasodilation and sympathetic mediated vasoconstriction in CKD. Understanding the mechanisms that impair vascular function within exercising muscle is important when understanding implications for systemic blood pressure regulation, cardiovascular disease and functional work capacity in CKD. Therefore, identifying a low cost, non-pharmaceutical intervention and its potential impact on improving vascular function in CKD is a priority in preventative cardiovascular disease medicine.
The present proposal aims to examine the effect of sympathetic vasoconstriction on the differential changes in exercising blood flow in response to acute oral supplementation with curcumin in patients with CKD.
3,840 studies on the registry are indexed under Kidney Diseases; 500 are open to participants now.
Browse Kidney Diseases studies →University of Iowa is the lead sponsor of 276 studies on the registry; 35 are open to participants now.
Of its 44 completed or terminated interventional studies of FDA-regulated products, 39 (89%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria for CKD subjects:
Age 45-80 years old CKD stage III and IV (estimated glomerular filtration rate: 15-60 mL/min/1.73m2) BMI \<40 kg/m2-1 Able to give informed consent
Exclusion Criteria for CKD subjects will include answering yes to the following questions:
Inclusion Criteria for healthy middle-age and older subjects:
Age 45-80 years old BMI \<40 kg/m2 1 Able to give informed consent
Exclusion Criteria for health older subjects will include answering yes to the following questions:
Patients will receive curcumin (Longvida) 2000 mg one time prior to exercise trials
Drug: Curcumin
Patients will receive placebo pill identical in appearance and taste to the supplement
Other: Placebo
Oral supplement one time at 2,000 mg
Also known as: Longvida
Oral supplement one time at 2,000 mg
%change forearm vascular condutance (FVC)
Percentage reduction in FVC in response to acute sympathetic stimulus (cold pressor test; CPT)
Time frame: 2 hours
forearm blood flow (FBF)
steady state FBF during forearm hand-grip exercise and CPT
Time frame: 2 hours
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
This study is withdrawn, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Iowa